Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics Inc expected to post a loss of $2.16 a share - Earnings Preview

* eFFECTOR Therapeutics Inc  EFTR.OQ   EFTR.O  is expected
to show
no change in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for eFFECTOR Therapeutics
Inc is
for a loss of $2.16 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 24.9%
in the last three months. ​
    * Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $11.00​, above​ its last closing price
of $2.16. ​​​

This summary was machine generated May 3 at 11:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Effector Therapeutics

See all news